A subgroup analysis of the RTOG 9601 trial, which stratified participants according to their pretreatment serum PSA levels, suggests disparate responses to therapy and potentially concerning cardiac and neurological effects in some men. However, subgroup analyses are notoriously difficult to interpret and the data should be considered with caution before changes are made to clinical practice.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Locke, J. et al. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat. Rev. Urol. 12, 193–204 (2015).
Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017).
Carrie, C. et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 17, 747–756 (2016).
Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019).
Valicenti, R. K. et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int. J. Radiat. Oncol. Biol. Phys. 86, 822–828 (2013).
Dess, R. T. et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 6, 735–743 (2020).
Sun, X. et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 344, e1553 (2012).
Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).
Wirth, M. P. et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer Program at median follow-up of 5.4 years. J. Urol. 172, 1865–1870 (2004).
Zapatero, A. et al. Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial. Int. J. Radiat. Oncol. Biol. Phys. 96, 341–348 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Dal Pra, A., Pollack, A. Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. Nat Rev Urol 17, 489–490 (2020). https://doi.org/10.1038/s41585-020-0333-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-0333-9